UROwebinar: The role of risk stratification of prostate cancer

This is the second episode of the new UROwebinar series “Prostate Cancer Screening: PRAISE U training toolbox” organised by the European School of Urology, the  EAU Policy Office, and the PRAISE-U Consortium. A recap of the previous episode will be part of the introduction.

This UROwebinar examines the emerging role of risk stratification in prostate cancer (PCa) screening, highlighting how predictive models and biomarkers are reshaping screening strategies and clinical decision-making. The experts will discuss how various factors—such as PSA levels, MRI findings, genetic markers, and clinical data—are integrated into risk models to refine screening recommendations. A presentation will also cover long-term risk assessment and the impact of age, family history, and PSA thresholds on screening protocols.

Additionally, the UROwebinar will explore the growing role of genetic testing in prostate cancer risk prediction, including the significance of BRCA1/2 mutations, Lynch syndrome, and other genetic risk calculators. The presenters will discuss how genetic information is incorporated into predictive models and its implications for personalised screening and treatment.

The UROwebinar will also address the challenges and benefits of integrating genetic testing into clinical practice, as well as future advancements in PCa risk assessment.